Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

Pace, David; Pollard, Andrew J.
October 2007
Archives of Disease in Childhood;Oct2007, Vol. 92 Issue 10, p909
Academic Journal
Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1 999, have been used successfully in Australia, Canada and several other European countries. Combination conjugate vaccines, containing more than. one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W-135 conjugate vaccine was licensed For use in 11–55 year old adolescents and adults in the US in January 2005, and subsequently also in 2–11 year old children in Canada in May 2006. This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis.


Related Articles

  • Preventing Meningococcal Infections in India. MITTAL, S. K.; MANCHANDA, VIKAS // Indian Pediatrics;Jun2014, Vol. 51 Issue 6, p446 

    The author reflects on the need to carefully select vaccines against meningococcus available in India to ensure maximum efficacy. Topics discussed include the inherent disadvantage of polysaccharide vaccine for lacking T cell response, a study which showed 90 to 100 percent sero-efficacy of...

  • New meningococcal glycoconjugate vaccine safe, effective in infants. Southall, Jennifer // Infectious Diseases in Children;Feb2008, Vol. 21 Issue 2, p24 

    The article discusses research being done on the effectiveness of a tetravalent meningococcal glycoconjugate vaccine. It references a study by Steven Black and colleagues, published in the "Journal of the American Medical Association." The study was conducted among infants aged 2 months in Great...

  • Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization. Vu, David M.; Kelly, Dominic; Heath, Paul T.; McCarthy, Noel D.; Pollard, Andrew J.; Granoff, Dan M. // Journal of Infectious Diseases;7/15/2006, Vol. 194 Issue 2, p231 

    Background. Group C meningococcal conjugate-vaccine effectiveness in the United Kingdom declines from ∼90% in the first year to 0% between 1 and 4 years after immunization in infants immunized at 2, 3, and 4 months of age and to 61% in toddlers given a single dose. Confidence intervals are...

  • Children in care missing out on jabs.  // Community Care;2/20/2003, Issue 1460, p15 

    Presents information on the study of immunization status of all children in several health districts in Great Britain. Percentage of children in public care who did not receive meningococcal C vaccine; Percentage of children in public care who moved placement more than three times in 2001.

  • Routine meningococcal vax warranted among US adolescents.  // PharmacoEconomics & Outcomes News;2/25/2006, Issue 497, p8 

    Discusses research on the cost effectiveness of routine vaccination against meningococcal infections in U.S. adolescents. Reference to a study by L. Coudeville et al, presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy held in December 2005; Conjugate vaccine...

  • THE ANTI NEISSERIA MENINGITIDES B VACCINE OVERCOME THE THYMUS INDEPENDENCE OF POLYSACCHARIDE C IN TODDLER. Pérez, O.; Lastre, M.; Bracho, G.; Del Campo, J.; Rodríguez, T.; Zayas, C.; Taboada, C.; Sierra, G. // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    VA-MENGOC-BCâ„¢ is an outer membrane protein based vaccine of serogroup B of Neisseria meningitidis. It also contains the serogroup C polysaccharide (PsC) which is non-covalently incorporated. We recently demonstrated the participation of other mechanisms possibly involved in it's protection...

  • Routine vaccination with polysaccharide meningococcal vaccines is an effective and possibly harmful strategy. Birmingham, M.E.; Lewis, R.F.; Perea, W.; Nelson, C.B.; Kabore, A.; Tarantola, D. // Bulletin of the World Health Organization;2003, Vol. 81 Issue 10, p751 

    Researchers suggest that mass campaigns followed by routine vaccination in the meningitis belt would be more effective against epidemic and endemic meningococcal meningitis than the current outbreak response strategy. They propose two doses of group A meningococcal polysaccharide vaccine for...

  • Subtractive Genomics Approach for in Silico Identification and Characterization of Novel Drug Targets in Neisseria Meningitides Serogroup B. Sarangi, Aditya Narayan; Aggarwal, Rakesh; Rahman, Qamar; Trivedi, Nidhi // Journal of Computer Science & Systems Biology;Sep-Oct2009, Vol. 2 Issue 5, p255 

    Meningococcal disease is a life-threatening illness with annual incidence rates varying from 1 to 1000 per 100 000 persons in different parts of the world. Effective polysaccharide and polysaccharide-protein conjugate vaccines that offer protection against infection with meningococcal serogroups...

  • Fragmentación del polisacárido de Neisseria meningitidis serogrupo C para su uso en vacunas conjugadas. Cabrera, Osmir; Soto, Carmen R.; Cuello, Maribel; Martínez, Miguel E.; Martínez, Juan C.; Sierra, Gustavo // Revista VacciMonitor (Vacunología y Temas Afines);Oct2001, Vol. 10 Issue 4, p1 

    Meningococcal infections are an important cause of morbidity and mortality worldwide. Serogroups B and C strains are responsible for most cases in the developed world. Meningococcal vaccines containing purified serogroup C capsular polysaccharide induce protective serum bactericidal antibodies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics